ADAGIO THERAPEUTICS INC's ticker is and the CUSIP is 00534A102. A total of 58 filers reported holding ADAGIO THERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is 0.14 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $248,596 | -82.1% | 225,996 | -27.7% | 0.00% | -100.0% |
| Q1 2024 | $1,387,185 | +189.0% | 312,429 | +156.5% | 0.00% | +100.0% |
| Q4 2023 | $479,916 | +1486.1% | 121,806 | +584.3% | 0.00% | – |
| Q3 2023 | $30,258 | -61.8% | 17,799 | -76.4% | 0.00% | – |
| Q2 2023 | $79,307 | – | 75,530 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| M28 Capital Management LP | 6,398,250 | $29,176,000 | 26.83% |
| Foresite Capital Management V, LLC | 1,431,826 | $6,529,000 | 2.67% |
| Slate Path Capital LP | 3,735,000 | $17,032,000 | 0.87% |
| Bain Capital Life Sciences Investors, LLC | 1,937,207 | $8,834,000 | 0.86% |
| Alphabet Inc. | 5,680,785 | $25,904,000 | 0.84% |
| 683 Capital Management, LLC | 2,350,000 | $10,716,000 | 0.57% |
| Orbimed Advisors | 5,056,000 | $23,055,000 | 0.37% |
| Redmile Group, LLC | 1,920,960 | $8,760,000 | 0.27% |
| Artal Group S.A. | 1,000,000 | $4,560,000 | 0.19% |
| Triatomic Management LP | 25,800 | $118,000 | 0.10% |